Studi clinici aperti all’arruolamento
Titolo: KRT232-117 – “An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)”
Principal Investigator: Prof. Pierfrancesco Tassone
Per informazioni sull’arruolamento contattare: Dott.ssa Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com
Studi clinici chiusi all’arruolamento
Titolo: LNA-i-miR-221 – “A dose escalation phase I study of LNA-i-miR-221 for the treatment of refractory multiple myeloma and advanced solid tumors”
Sponsor: Azienda Ospedaliero-Universitaria Mater Domini Catanzaro – Studio Clinico di Fase I spontaneo supportato da progetto AIRC 5×1000
Principal Investigator: Prof. Pierfrancesco Tassone